Impact on Daily Practice Is Completely Unknown

Article

For independent physician practices, the realities of overhead expenses, time available for patient care, and regulatory requirements can only be assessed when the specific requirements for reporting and reimbursement are clear.

Array

Recent Videos
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Related Content
The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

FDA Approves FoundationOne CDx Diagnostic for Tovorafenib in Brain Tumors

Roman Fabbricatore
January 20th 2025
Article

The approval marks Foundation Medicine’s first companion diagnostic indication to exclusively support pediatric patients with brain tumors.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Integrating Psilocybin-Assisted Psychotherapy in Comprehensive Cancer Care

Michael P. Bogenschutz, MD
January 20th 2025
Article

Micheal P. Bogenschutz, MD, discussed addressing unmet needs, implementation, and adverse effects related to psilocybin-assisted psychotherapy in cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS

Tim Cortese
January 18th 2025
Article

The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

UGN-102 May Be Nonsurgical Alternative to TURBT in Low-grade Bladder Cancer

Tim Cortese
January 18th 2025
Article

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.